Denali Therapeutics (NASDAQ:DNLI) used an analyst call from the 2026 WORLD Symposium in San Diego to highlight new and ...
Analysis from continued follow-up of Phase 1/2 clinical trial data in Hunter syndrome (MPS II) reinforces potential for tividenofusp alfa ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results